Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: • Strong rebound • Overbought risk • Volatile swing Support Level: $71.65–$74.30 Resistance Level: $88.70–$89.00 ARWR remains constructive after a strong rebound from the low-$70s to the high-$80s, but it is short-term stretched and needs to hold above the mid-$80s to avoid a pullback toward support.
Sentiment & News
Key News Insights: • Phase 3 Win • Analyst Support • Institutional Buying Arrowhead's positive Phase 3 plozasiran data in severe hypertriglyceridemia, plus rising analyst and institutional interest, has sharply boosted sentiment and underscored a near-term commercial catalyst.
AI Summary
Arrowhead has evolved from a pure pipeline bet into a commercial execution story—REDEMPLO and strong plozasiran data materially de-risk the platform, but with the stock already rerated and revenue still tiny versus burn, the key investment question is whether script growth and payer adoption can prove a durable launch before the current optimism fades.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 4 | Feb 11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment. | Closed | -9.6% |
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |